|Bid||110.12 x 800|
|Ask||110.21 x 800|
|Day's range||107.25 - 110.47|
|52-week range||100.08 - 188.99|
|Beta (5Y monthly)||0.21|
|PE ratio (TTM)||3.90|
|Earnings date||07 Aug 2023|
|Forward dividend & yield||N/A (N/A)|
|Ex-dividend date||02 June 2022|
|1y target est||167.51|
BioNTech (BNTX) announces positive initial data evaluating BNT316/ONC-392 to treat metastatic non-small cell lung cancer.
Shares of BioNTech (NASDAQ: BNTX) were up as by much as 5.3% on Friday before closing the session up 3.85% after the biotech company announced positive news regarding a clinical trial for its non-small cell lung cancer therapy candidate. The company focuses on immunotherapies to treat cancer, infectious diseases, and other diseases. BioNTech's shares have been sliding because sales of Comirnaty, the COVID-19 vaccine it developed with Pfizer, are falling.
BNT316/ONC-392 is a next-generation anti-CTLA-4 monoclonal antibody candidate jointly developed by BioNTech and OncoC4 as monotherapy or combination therapy in a range of solid tumor indications, including non-small cell lung cancer (NSCLC)Interim data of BNT316/ONC-392 from the ongoing Phase 1/2 trial to be presented at this year’s ASCO Annual Meeting demonstrate encouraging signs of clinical anti-tumor activity and a manageable safety profile in patients with metastatic, PD-(L)1-resistant NSCL
Novavax's (NVAX) protein-based COVID-19 vaccine gets recommendation for full marketing authorization in COVID-19 patients from European Medicines Agency.
Revised contract addresses concerns over costly glut of unwanted shots as public health threat wanes
One of the best investment strategies is to buy shares of companies that are presently beaten down by the market, but in whose businesses you have full confidence for growth over the long term. Then, as the market bids up their valuation over time, you'll get the benefit of both the company's actual growth as well as its strengthening reputation among other investors. Two stocks the market is ignoring today, but could likely become excellent investments in the next decade, are in the biotechnology space.
Investors need to pay close attention to BioNTech (BNTX) stock based on the movements in the options market lately.
Image source: The Motley Fool. BioNTech Se (NASDAQ: BNTX)Q1 2023 Earnings CallMay 08, 2023, 8:00 a.m. ETContents: Prepared Remarks Questions and Answers Call Participants Prepared Remarks: OperatorWelcome to the BioNTech first quarter 2023 update call.
COVID-19 vaccine franchise focused on vaccine adaptation readiness ahead of the fall season and advancing next generation vaccine candidates and combinationsBioNTech and partner OncoC4 plan to start a Phase 3 clinical trial evaluating anti-CTLA-4 antibody BNT316 (ONC-392) as monotherapy in NSCLC patients who progress after PD-1/PD-L1 treatment Added new class of precision therapeutics to clinical-stage oncology portfolio, with next-generation Antibody-Drug Conjugate (ADC) candidatesPresenting cl
MAINZ, Germany, April 24, 2023 (GLOBE NEWSWIRE) – BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will announce its financial results for the first quarter 2023 on Monday, May 8th, 2023. BioNTech invites investors and the general public to join a conference call and webcast with investment analysts on the same day at 8.00 a.m. EDT (2.00 p.m. CEST) to report its financial results and provide a corporate update for the first quarter 2023. To access the live conference call via telephone, p
To simplify the COVID-19 vaccination schedule for all individuals, the FDA authorizes using bivalent COVID-19 vaccines for all doses administered to individuals aged six years and older.
With its stock down 11% over the past three months, it is easy to disregard BioNTech (NASDAQ:BNTX). However, stock...
It hasn't been the best quarter for BioNTech SE ( NASDAQ:BNTX ) shareholders, since the share price has fallen 17% in...
Key Insights The projected fair value for BioNTech is US$219 based on 2 Stage Free Cash Flow to Equity BioNTech is...
Companies seek compensation for Pfizer’s and BioNTech’s unlicensed use of patented technologies in COVID-19 mRNA-LNP vaccines WARMINSTER, Pa., April 04, 2023 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus”), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral diseases, and Genevant Sciences (Genevant) today filed a lawsuit in the U.S. District Court for the District of New Jers
BioNTech receives exclusive licenses from DualityBio for two investigational antibody-drug conjugate assets (DB-1303 and DB-1311) directed against targets expressed in a broad range of human cancersCollaboration will add a new class of precision medicine therapeutics to BioNTech’s clinical-stage oncology portfolio, expanding the breadth of its immunotherapy toolkit with synergistic potentialDualityBio receives upfront payments totaling $170 million, and will be eligible to receive development, r
In the latest trading session, BioNTech SE Sponsored ADR (BNTX) closed at $124.57, marking a +1.63% move from the previous day.
Wynn Resorts and BioNTech have been highlighted as Zacks Bull and Bear of the Day.
MAINZ, Germany, March 28, 2023 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, “BioNTech” or the “Company”) today announced that it has entered into a new share repurchase program (the “Program”), pursuant to which the Company may purchase American Depositary Shares, each representing one ordinary share (“ADS”), of the Company in the amount of up to $0.5 billion during the remainder of 2023. BioNTech expects to use all or a portion of the repurchased ADSs and the ADSs held in treasury to satisfy
BNTX is ranked a lowly 5 for a reason. Earnings have peaked, COVID hysteria has subsided, and the technical picture is lagging.
Shares of vaccine maker BioNTech (NASDAQ: BNTX) were down 2.8% early Monday afternoon after falling as much as 6.4% earlier in the day. Annual earnings per share (EPS) also dropped a bit, from 39.63 euros ($42.76) to 37.77 euros ($40.77). In the long run, BioNTech may still be a good deal.
Yahoo Finance Live’s Julie Hyman breaks down the decline in stock for BioNTech.
By Liz Moyer
Expanded and advanced oncology pipeline to 20 programs in 24 ongoing clinical trials including five ongoing randomized Phase 2 clinical trials; multiple trials with registrational potential expected to be initiated in 2023 and 2024Announced licensing agreement with OncoC4 to complement the Company’s oncology portfolio with clinical stage next-generation immune checkpoint modulator; a randomized Phase 3 trial planned to start in 2023Initiated Phase 1 trials for four mRNA vaccine candidates in the
Key Insights The considerable ownership by private equity firms in BioNTech indicates that they collectively have a...